KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Accumulated Expenses (2016 - 2025)

Rigel Pharmaceuticals has reported Accumulated Expenses over the past 16 years, most recently at $11.9 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 17.51% year-over-year to $11.9 million; the TTM value through Dec 2025 reached $11.9 million, up 17.51%, while the annual FY2025 figure was $11.9 million, 17.51% up from the prior year.
  • Accumulated Expenses for Q4 2025 was $11.9 million at Rigel Pharmaceuticals, up from $10.1 million in the prior quarter.
  • Over five years, Accumulated Expenses peaked at $11.9 million in Q4 2025 and troughed at $5.2 million in Q1 2024.
  • A 5-year average of $8.1 million and a median of $7.9 million in 2024 define the central range for Accumulated Expenses.
  • Biggest five-year swings in Accumulated Expenses: dropped 17.06% in 2022 and later grew 27.02% in 2025.
  • Year by year, Accumulated Expenses stood at $10.7 million in 2021, then decreased by 17.06% to $8.9 million in 2022, then dropped by 2.14% to $8.7 million in 2023, then grew by 16.86% to $10.1 million in 2024, then rose by 17.51% to $11.9 million in 2025.
  • Business Quant data shows Accumulated Expenses for RIGL at $11.9 million in Q4 2025, $10.1 million in Q3 2025, and $7.9 million in Q2 2025.